Genmab drug epcoritamab reduces lymphoma progression or death risk by 51%
Genmab and AbbVie announced that their drug epcoritamab, when added to standard treatment for newly diagnosed diffuse large B-cell lymphoma, reduced the risk of cancer worsening or death by 51% compared to standard treatment alone.
Genmab and AbbVie said epcoritamab, when added to the current standard treatment for newly diagnosed diffuse large B-cell lymphoma, reduced the risk of the cancer worsening or patients dying by 51% versus standard treatment alone. Diffuse large B-cell lymphoma, or DLBCL, is an…